Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE011 (ITA) (Dr. Jansen)
· consented 2022-04-02
Adverse events
4
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-10-06 (study day 171); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-30 (study day 195); relationship: Y
mild
assessed
2026-08-18
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-12-30 (study day 256); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-01-09 (study day 266); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.